Epigenetics and epigenetic alterations in pancreatic cancer

Noriyuki Omura, Michael S Goggins

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer remains a major therapeutic challenge. In 2008, there will be approximately 37,680 new cases and 34,290 deaths attributable to pancreatic cancer in the United States (U.S.), making it the fourth leading cause of cancer-related death. Recent comprehensive pancreatic cancer genome project found that pancreatic adenocarcinomas harbored 63 intragenic mutations or amplifications/homozygous deletions and these alterations clustered in 12 signaling pathways. In addition to widespread genetic alterations, it is now apparent that epigenetic mechanisms are also central to the evolution and progression of human cancers. Since epigenetic silencing processes are mitotically heritable, they can drive neoplastic progression and undergo the same selective pressure as genetic alterations. This review will describe recent developments in cancer epigenetics and their importance in our understanding of pancreatic adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)310-326
Number of pages17
JournalInternational Journal of Clinical and Experimental Pathology
Volume2
Issue number4
StatePublished - 2009

Fingerprint

Pancreatic Neoplasms
Epigenomics
Adenocarcinoma
Genetic Epigenesis
Neoplasms
Genome
Mutation
Therapeutics

Keywords

  • Epigenetics
  • Pancreatic cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Epigenetics and epigenetic alterations in pancreatic cancer. / Omura, Noriyuki; Goggins, Michael S.

In: International Journal of Clinical and Experimental Pathology, Vol. 2, No. 4, 2009, p. 310-326.

Research output: Contribution to journalArticle

@article{185a5be913974cf785ad74658ba3f254,
title = "Epigenetics and epigenetic alterations in pancreatic cancer",
abstract = "Pancreatic cancer remains a major therapeutic challenge. In 2008, there will be approximately 37,680 new cases and 34,290 deaths attributable to pancreatic cancer in the United States (U.S.), making it the fourth leading cause of cancer-related death. Recent comprehensive pancreatic cancer genome project found that pancreatic adenocarcinomas harbored 63 intragenic mutations or amplifications/homozygous deletions and these alterations clustered in 12 signaling pathways. In addition to widespread genetic alterations, it is now apparent that epigenetic mechanisms are also central to the evolution and progression of human cancers. Since epigenetic silencing processes are mitotically heritable, they can drive neoplastic progression and undergo the same selective pressure as genetic alterations. This review will describe recent developments in cancer epigenetics and their importance in our understanding of pancreatic adenocarcinoma.",
keywords = "Epigenetics, Pancreatic cancer",
author = "Noriyuki Omura and Goggins, {Michael S}",
year = "2009",
language = "English (US)",
volume = "2",
pages = "310--326",
journal = "International Journal of Clinical and Experimental Pathology",
issn = "1936-2625",
publisher = "e-Century Publishing Corporation",
number = "4",

}

TY - JOUR

T1 - Epigenetics and epigenetic alterations in pancreatic cancer

AU - Omura, Noriyuki

AU - Goggins, Michael S

PY - 2009

Y1 - 2009

N2 - Pancreatic cancer remains a major therapeutic challenge. In 2008, there will be approximately 37,680 new cases and 34,290 deaths attributable to pancreatic cancer in the United States (U.S.), making it the fourth leading cause of cancer-related death. Recent comprehensive pancreatic cancer genome project found that pancreatic adenocarcinomas harbored 63 intragenic mutations or amplifications/homozygous deletions and these alterations clustered in 12 signaling pathways. In addition to widespread genetic alterations, it is now apparent that epigenetic mechanisms are also central to the evolution and progression of human cancers. Since epigenetic silencing processes are mitotically heritable, they can drive neoplastic progression and undergo the same selective pressure as genetic alterations. This review will describe recent developments in cancer epigenetics and their importance in our understanding of pancreatic adenocarcinoma.

AB - Pancreatic cancer remains a major therapeutic challenge. In 2008, there will be approximately 37,680 new cases and 34,290 deaths attributable to pancreatic cancer in the United States (U.S.), making it the fourth leading cause of cancer-related death. Recent comprehensive pancreatic cancer genome project found that pancreatic adenocarcinomas harbored 63 intragenic mutations or amplifications/homozygous deletions and these alterations clustered in 12 signaling pathways. In addition to widespread genetic alterations, it is now apparent that epigenetic mechanisms are also central to the evolution and progression of human cancers. Since epigenetic silencing processes are mitotically heritable, they can drive neoplastic progression and undergo the same selective pressure as genetic alterations. This review will describe recent developments in cancer epigenetics and their importance in our understanding of pancreatic adenocarcinoma.

KW - Epigenetics

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=67149130222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67149130222&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 310

EP - 326

JO - International Journal of Clinical and Experimental Pathology

JF - International Journal of Clinical and Experimental Pathology

SN - 1936-2625

IS - 4

ER -